# 1 Immunogenicity, reactogenicity, and IgE-mediated immune responses of a mixed

2 whole-cell and acellular pertussis vaccine schedule in Australian infants: a

# 3 randomised, double-blind, non-inferiority trial

4 Gladymar Pérez Chacón, Marie J Estcourt, James Totterdell, Julie A Marsh, Kirsten P Perrett,

5 Dianne E Campbell, Nicholas Wood, Michael Gold, Claire S Waddington, Michael O' Sullivan,

6 Sonia McAlister, Nigel Curtis, Mark Jones, Peter B McIntyre, Patrick G Holt, Peter C Richmond,

7 Tom Snelling\*

8 Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Nedlands, 9 Western Australia, Australia (G Pérez Chacón PhD, J Marsh PhD, S McAlister BSc First Class 10 Honours, Prof PC Richmond FRACP, Prof T Snelling PhD); School of Population Health, Faculty of 11 Health Science, Curtin University, Western Australia, Australia (G Pérez Chacón PhD, Prof T Snelling PhD); Sydney School of Public Health, Faculty of Medicine and Health, University of 12 13 Sydney, Sydney, New South Wales, Australia (MJ Estcourt PhD, J Totterdell M Biostatistics, M 14 Jones M Biostatistics, Prof T Snelling PhD); Royal Children's Hospital, Murdoch Children's 15 Research Institute, Parkville, Victoria, Australia (Prof KP Perrett PhD); Department of 16 Paediatrics, The University of Melbourne, Melbourne, Victoria, Australia (Prof KP Perrett PhD, 17 Prof N Curtis PhD); Department of Allergy and Immunology, The Children's Hospital at 18 Westmead, Sydney, New South Wales, Australia (Prof DE Campbell, PhD); Discipline of Child and 19 Adolescent Health, The University of Sydney, Sydney, New South Wales, Australia (Prof DE 20 Campbell, PhD; Prof N Wood, PhD); The Children's Hospital at Westmead, Sydney, New South 21 Wales, Australia (Prof N Wood, PhD); Discipline of Paediatrics, School of Medicine, University of 22 Adelaide, Adelaide, South Australia, Australia (Prof M Gold FRACP); Department of Medicine, 23 University of Cambridge, Cambridge, UK (CS Waddington DPhil); Department of Immunology, 24 Perth Children's Hospital, Nedlands, Western Australia, Australia (M O'Sullivan, FRACP FRCPA); 25 Division of Paediatrics, School of Medicine, The University of Western Australia, Perth, Western 26 Australia, Australia (S McAlister BSc Firs Class Honours; M O'Sullivan FRACP, FRCPA; Prof PC 27 Richmond FRACP); Telethon Kids Institute, Nedlands, Western Australia, Australia (M O'Sullivan, 28 FRACP, FRCPA), Infectious Diseases Unit, Royal Children's Hospital Melbourne, Parkville, Victoria, 29 Australia (Prof Nigel Curtis PhD); Infectious Diseases Group, Murdoch Children's Research 30 Institute, Parkville, Victoria, Australia (Prof N Curtis PhD); Dunedin School of Medicine, University 31 of Otago, New Zealand (Prof PB McIntyre, DMedSc); Wal-yan Respiratory Research Centre, 32 Telethon Kids Institute, University of Western Australia, Nedlands, Western Australia, Australia 33 (Prof PG Holt PhD)

\*Corresponding author: Prof Tom Snelling – Head, Health and Clinical Analytics Lab, Sydney
 School of Public Health, Faculty of Medicine and Health, The University of Sydney, Australia.

- 36 Address: Rm 123, Edward Ford Building A27, The University of Sydney NSW (Australia), 2006.
- 37 Telephone: +61 2 9563 6886.
- 38 Email: tom.snelling@sydney.edu.au
- 39

## 40 *Summary*

## 41 Background

In most high-income countries, infant vaccination with acellular pertussis (aP) vaccines is the standard of care for the prevention of pertussis disease. Based on immunological and epidemiological evidence, we hypothesised that substitution of the first aP dose in the vaccination schedule with whole-cell (wP) vaccine might protect against the development of IgEmediated food allergy. Here we report the results of a randomised comparison of the reactogenicity, immunogenicity, and IgE-mediated immune responses of a mixed wP/aP primary schedule versus the standard aP-only schedule.

## 49 Methods

50 OPTIMUM is a Bayesian, two-stage, double-blind, group sequential trial, enrolling healthy 51 Australian-born infants. At approximately 6 weeks old, participants are randomly assigned (1:1) 52 to a first dose of a pentavalent wP combination vaccine (DTwP-Hib-HepB; Pentabio, PT Bio Farma, 53 Indonesia) versus a hexavalent aP vaccine, which includes inactivated poliovirus vaccine (IPV) 54 types 1, 2, and 3 in its formulation (DTaP-Hib-HepB-IPV; Infanrix Hexa, GlaxoSmithKline, 55 Australia). All infants receive a hexavalent aP vaccine at 4 and 6 months old, as well as a 56 tetravalent aP-based formulation at 18 months old (DTaP-IPV; Infanrix-IPV, GlaxoSmithKline, Australia) to ensure at least three doses of IPV as part of their childhood schedule while 57 58 preserving blinding. In stage one, pertussis antigen-specific IgG responses were measured before 59 and approximately one month after the 6-month aP vaccine doses. The immunogenicity of the 60 mixed schedule (wP/aP/aP) was defined as being non-inferior to that of the aP-only schedule

3

(aP/aP/aP) using a non-inferiority margin of 2/3 on the ratio of the geometric mean
concentrations of pertussis toxin (PT) IgG approximately one month after the 6-month aP dose.
Solicited adverse reactions were summarised by study arm and included all children who received
the first dose of either wP or aP. Parental acceptance was assessed using a 5-point Likert scale.
The trial is registered with ANZCTR (ACTRN12617000065392p).

# 66 Results

67 Between March 7, 2018 and January 13, 2020, 150 infants were randomised (75 per arm). 68 Demographic and baseline characteristics were balanced across the study arms. Most infants 69 were born to aP-vaccinated mothers. In the intent-to-treat analysis, PT-IgG responses of the 70 mixed schedule were non-inferior to the aP-only schedule approximately one month after a 6-71 month aP dose [geometric mean ratio (GMR) = 0.98, 95% Bayesian credible interval (0.77 to 1.26); 72 probability (GMR > 2/3) > 0.99]. Severe solicited systemic adverse reactions were reported 73 among 14 of 74 (19%) infants after a first dose of wP and among 8 of 72 (11%) infants after a first 74 dose of aP; irritability after the first dose of pertussis-containing vaccine was the most frequent 75 severe event (11 of 74 [15%] wP recipients versus 7 of 72 [10%] aP recipients). Within 6 months of enrolment, 7 serious adverse events were reported, with none deemed related to the study 76 77 vaccines. Parental acceptance of the mixed schedule was high (97% would agree to have this 78 schedule again).

# 79 Interpretation

- 80 The mixed wP/aP schedule was associated with more reactions than the aP-only schedule, but
- 81 these were mostly non-severe. The mixed schedule was well accepted by parents and evoked
- 82 non-inferior PT-IgG responses after completion of the three-dose primary series.
- 83 Funding
- 84 Telethon New Children's Hospital Research Fund and National Health and Medicine Research
- 85 Council.
- 86

#### It is made available under a CC-BY-ND 4.0 International license .

## 5

# 87 *Research in context*

We searched PubMed on April 17, 2023, for paediatric studies of heterologous priming with whole-cell pertussis (wP) vaccine and acellular pertussis (aP) vaccine, with no language or date restrictions. We used the terms ["whole-cell pertussis vaccine" AND "acellular pertussis vaccine"], OR ["IgE" AND "tetanus toxoid"]. Of the 997 articles retrieved, we found no published randomised comparisons between heterologous versus exclusive primary routine vaccination with either wP or aP-based formulations.

In two observational studies, laboratory-confirmed pertussis disease was less common among
school-aged children and adolescents who received wP versus aP as a first dose. A heterologous
wP/aP primary schedule (in which the first dose was wP) was associated with lower rates of
pertussis disease than an aP-only primary schedule.

98 In a case-control study, pertussis was less common among children who had received mixed wP/three-component (3c)-aP vaccine (including pertussis toxoid, filamentous haemagglutinin, 99 100 and pertactin) versus those exclusively primed with 3c-aP vaccine formulations. No evidence of 101 a difference was observed among those vaccinated with a heterologous wP/five-component (5c)-102 aP primary schedule versus those exclusively primed with a 5c-aP vaccine formulation (including 103 the above-mentioned pertussis antigens as well as fimbriae type 2 and 3). In contrast, another 104 case-control study found that compared to the 5c-aP-only priming strategy, a primary series 105 including one or more doses of a wP vaccine formulation, with reported efficacy against 106 laboratory-confirmed pertussis between 36% (95% CI 14% to 52%) and 48% (95% 37% to 58%), 107 was associated with higher vaccine effectiveness against pertussis disease more than a decade

### It is made available under a CC-BY-ND 4.0 International license .

6

after priming. In none of the case-control analyses was the nature of the heterologous schedulesfurther described.

- 110 Two clinical and immunological studies reported that wP-only schedules were associated with
- 111 lower post-priming tetanus toxoid (TT)-IgE concentrations than homologous priming with aP-
- 112 containing vaccines. An additional study reported lower TT-IgE concentrations after a first dose
- 113 of wP versus aP.

# 114 Added value of this study

- 115 To our knowledge, this is the first trial to evaluate the immunogenicity, reactogenicity, and IgE-
- 116 mediated immune responses to a mixed primary schedule consisting of a first dose of wP given
- at approximately 6 weeks old, followed by aP at 4, and 6 months old.
- 118 Implications of all the available evidence
- This trial provides supporting evidence of the safety and immunogenicity of a mixed wP/aP vaccine schedule in a setting with high maternal pertussis vaccine coverage. The findings warrant further investigation of the comparative clinical effects of a mixed wP/aP versus the standard aPonly schedule.
- 123

7

# 124 Introduction

Whole-cell pertussis (wP) vaccines cause adverse reactions in infants frequently, but these are generally benign and self-limited.<sup>1</sup> Since the early 1990s, wP vaccine formulations have been discontinued from use in most high- and some middle-income countries and replaced by less reactogenic subunit acellular (aP) vaccines.<sup>2</sup> Data from pertussis outbreaks suggest that primary schedules comprising at least one wP vaccine dose provide better long-term protection than aPonly primary schedules.<sup>3,4</sup>

131 We have previously reported that compared to matched population controls, Australian children with IgE-mediated food allergy were less likely to have received wP rather than aP as their first 132 pertussis vaccine dose in infancy (odds ratio [OR] 0.77; 95% CI 0.62 to 0.95).<sup>5</sup> Consistent with this 133 134 observation, previous studies have described differences in the immune effects arising from 135 vaccination with wP versus aP vaccines in infancy. Compared to exclusive vaccination with aP which elicits a Th<sub>2</sub>-polarised immunophenotype, a first dose of wP induces relative  $Th_1/Th_{17}$ 136 137 immune polarisation, reducing the production of aP antigen-specific type 2 cytokines and down-138 regulating the synthesis of total IgE, and specific IgE responses against tetanus toxoid (TT), diphtheria toxoid (DT), pertussis toxin (PT), and food antigens.<sup>6–11</sup> We therefore hypothesise that 139 140 mixed priming using a first dose of wP followed by aP vaccine doses could protect against IgE-141 mediated food allergy, while offering non-inferior protection against pertussis and an acceptable 142 reactogenicity profile. To test this, we are conducting a two-stage randomised controlled trial 143 (RCT) to assess clinical, immunological, and safety endpoints in Australian infants vaccinated with 144 a mixed (wP/aP/aP) primary vaccine schedule, compared with the standard aP-only (aP/aP/aP) 145 vaccine schedule.<sup>12,13</sup> Ahead of ascertainment of the primary clinical outcome of IgE-mediated

8

food allergy by 12 months old, here we present the immunogenicity and reactogenicity outcomes which were assessed in the first 150 infants enrolled in Perth, Western Australia (WA) at approximately 6 and 7 months old, as well as total IgE, TT, and food-antigen specific IgE responses at the same ages.

150 *Methods* 

## 151 Study design and participants

152 The OPTIMUM (Optimising Immunisation Using Mixed Schedules) study is a Bayesian group-153 sequential, two-stage, multicentre, randomised, parallel group, double-blind controlled trial with 154 an adaptive design. Stage one was designed to obtain detailed solicited reactogenicity data 155 following each pertussis vaccine dose and post-priming immune response data for the first 150 156 enrolled infants. Stage two was designed to assess the primary endpoint of IgE-mediated food 157 allergy, with less intensive follow-up, but with sufficient sample size to provide appropriate levels 158 of statistical power. The analyses that we describe here involve the first six months of follow-up 159 of the first 150 WA-born infants enrolled in stage one (Perth Children's Hospital/Telethon Kids 160 Institute, WA). The eligibility criteria, enrolment methods, and visit schedule are provided in the protocol and statistical analysis plan.<sup>12,13</sup> Eligible participants were healthy infants aged between 161 162 6 and < 12 weeks old and born after 32 weeks' gestation. The legally accepted representative(s) of each participating infant provided written informed consent. The trial was approved by the 163 164 Child and Adolescent Health Service Ethics Committee, WA, Australia (RGS 00019).

9

# 165 Randomisation and masking

166 Randomisation was by computer-generated allocation sequence prepared by the trial statistician, and based on randomly permuted blocks of size six, eight, or ten.<sup>12,13</sup> Infants were 167 168 assigned in a 1:1 ratio to receive either the intervention (pentavalent wP combination vaccine: 169 (DT, TT, wP, Haemophilus influenzae type b [Hib], and hepatitis B [HepB] vaccine; DTwP-Hib-170 HepB, Pentabio, PT Bio Farma, Indonesia) or the comparator (hexavalent aP combination vaccine, 171 which includes inactivated poliovirus vaccine [IPV] types 1, 2, and 3 in its formulation: DTaP-Hib-172 HepB-IPV, Infanrix Hexa, GlaxoSmithKline, Australia) at approximately 6 weeks old. An unblinded 173 research nurse obtained the next sequential vaccine allocation and prepared it into a syringe which was covered with an opaque label. Following vaccination, this nurse had no involvement 174 175 in subsequent study procedures. Parents of children in the stage one cohort were unblinded in 176 May 2023, after the last child completed the study.

## 177 Procedures

178 At approximately 6 weeks old ("Day 0"), an intramuscular dose (0.5 mL) of either a World Health 179 Organization (WHO)-pregualified pentavalent wP combination vaccine or a hexavalent aP combination vaccine was administered into the anterolateral aspect of the right thigh. At 180 181 approximately 4 and 6 months old, all participants received the standard (6-in-1) aP combination 182 vaccine (as routinely recommended by the Australian immunisation schedule) at the same 183 injection site (anterolateral aspect of the right thigh). The 13-valent pneumococcal conjugate 184 vaccine (13vPCV) and monovalent rotavirus vaccine (RV1) were co-administered at 185 approximately 6 weeks and 4 months old per Australian recommendations. National guidelines 186 also recommend all children receive at least three doses of IPV as part of their childhood

10

187 schedule; to ensure this was achieved while preserving blinding, children assigned to both the 188 mixed and the aP-only schedule received a dose of DTaP-IPV (Infanrix-IPV, GlaxoSmithKline, 189 Australia) at 18 months old.<sup>14</sup> A prophylactic dose of paracetamol (15 mg/Kg) was administered 190 immediately before the 6-week doses per Australian guidelines for wP vaccines.<sup>15</sup> Two additional 191 doses 6-hour apart were recommended, but not observed by the researchers.

192 Solicited systemic and local adverse reactions following pertussis primary vaccinations were 193 ascertained once a day for 7 days and recorded by the participant's parent in a diary card. These 194 were fever (axillary temperature  $\geq$  38° C), irritability, restlessness, vomiting, diarrhoea, anorexia, 195 drowsiness, as well as erythema (redness), swelling, induration (hardness) and pain at the 196 injection-site. Serious adverse events (SAEs) were defined as any adverse event/adverse reaction 197 that resulted in death, was life-threatening, required hospitalisation or prolongation of existing 198 hospitalisation, resulted in persistent or significant disability or incapacity, or was a congenital anomaly, or birth defect.<sup>16</sup> The total number of SAEs and adverse events of special interest 199 200 (breakthrough pertussis infections and hypotonic hyporesponsive episodes) occurring within the 201 first 6 months of follow-up were reported. SAEs and unsolicited adverse events by treatment arm 202 will be reported at the end of the trial. To ascertain overall satisfaction of the vaccines 203 administered, parents were asked about their agreement with the statement: "I would be willing to vaccinate another child with the same combination of vaccines administered;" responses were 204 205 recorded in diary cards on Day 6 using a 5-point Likert scale, from "strongly disagree" to "strongly 206 agree".

207 Peripheral blood samples were obtained immediately before the 6-month aP dose, and 208 approximately one month (21 to 35 days) afterwards. Serum IgG responses to diphtheria,

11

209	tetanus, and pertussis antigens were measured using a multiplex fluorescent bead-based
210	immunoassay. <sup>17</sup> The threshold for seropositivity was defined as concentrations $\geq$ 5 IU/mL (5000
211	mIU/mL) for pertussis antigens (i.e., PT, filamentous haemagglutinin [FHA], pertactin [PRN], and
212	fimbriae type 2 and 3 [FIM2/3]). <sup>18</sup> Long-term seroprotective concentrations for TT and DT were
213	defined at ≥ 100 mIU/mL. <sup>19,20</sup> Total and specific IgE to hen's egg antigens and TT were measured
214	in plasma samples (ImmunoCAP, Thermo Fisher Scientific) using the limits of detection (LLoD)
215	and quantitation (LLoQ) specified by the manufacturer. The total IgE concentrations were
216	reported in the range of 0.1 kU/L to 100 kU/L for low-range assays or 2 to 5000 kU/L if exceeded.
217	IgE concentrations to specific antigens were reported in the range of 0.00 kU <sub>a</sub> /L to 100.00 kU <sub>a</sub> /L.
218	The LLoD for antigen/allergen specific IgE was ≥ 0.01 kU/L; the LLoQ for total and specific IgE was
219	≥ 0.1 kU <sub>(a)</sub> /L.

# 220 Outcomes

Vaccine immunogenicity outcomes included IgG responses to PT, FHA, PRN, tetanus, and diphtheria toxoids immediately before the 6-month aP dose and approximately one month later. Outcomes related to IgE-mediated immune responses included total IgE and specific IgE against hen's egg antigens and TT assessed immediately before the 6-month aP dose and approximately one month later. Reactogenicity and tolerability outcomes included the occurrence of specific solicited local and systemic adverse reactions in the 7 days following each scheduled dose, and the parent-reported acceptability of the doses administered.

## 228 Statistical analysis

The statistical analysis plan was written by the trial statistician and approved by study investigators prior to unblinding of group allocations.<sup>13</sup> Intention-to-treat (ITT) and per-protocol (PP) estimands were considered for each statistical model. The ITT analysis set included all infants who received at least the first dose of wP or aP, irrespective of any subsequent deviations from the study protocol. The PP analysis set included only infants with outcomes measured without deviation from the protocol-specified vaccination and blood collection schedules. Missing outcomes were assumed to be missing-at-random.

236 Immunogenicity and outcomes related to IgE-mediated immune responses were summarised by 237 the sample GMCs as well as seropositivity rate at each time-point. Each antigen/allergen type 238 was analysed using Bayesian multivariate-normal linear regression models on the available log<sub>10</sub> 239 concentrations with an unstructured covariance matrix shared across both treatment groups. 240 The geometric mean ratio (GMR) of the mixed schedule relative to the aP-only schedule at each 241 time-point was estimated. Analyses were conducted separately for the intent-to-treat (ITT) and 242 per-protocol (PP) sets. A non-inferiority margin of 2/3 on the GMR was used to assess the noninferiority of the mixed schedule versus the aP-only schedule with regards to PT-IgG 243 approximately one month after the 6-month aP dose per WHO guidelines.<sup>21</sup> To estimate the 244 245 models, IgE-specific values reported as 0.00 kU<sub>a</sub>/L were treated as left-censored at 0.005 kU<sub>a</sub>/L. 246 All adjusted models included sex, birth order, breastfeeding status, delivery method, family 247 history of atopic disease, and parental income as baseline covariates.

To supplement the IgG and IgE models of the raw concentrations, the event of IgG seropositivity for each vaccine antigen with respect to the specified threshold and IgE concentrations  $\geq 0.01$ 

13

250	KU/L were analysed via Bayesian logistic mixed effects models. The models were used to derive
251	standardised differences of the mixed schedule compared to the aP-only schedule for probability
252	of seropositivity and IgE $\geq$ 0.01 KU/L respectively. The reactogenicity data were summarised by
253	the distribution of each solicited adverse event for each vaccine occasion at the study site clinic
254	and the highest/worst reaction grade experienced. Analyses were performed in R version 4.3.1
255	with Bayesian models fit using Stan version 2.33.1 (via CmdStanR version 0.6.1). This trial is
256	registered at the Australian and New Zealand Clinical Trial Registry (ACTRN12617000065392p).
257	Role of the funding source
257 258	Role of the funding source This trial is funded by the Telethon New Children's Hospital Research Fund (stage one) and
257 258 259	Role of the funding source This trial is funded by the Telethon New Children's Hospital Research Fund (stage one) and Australia's National Health and Medicine Research Council (stage two). These funding bodies had
257 258 259 260	Role of the funding source This trial is funded by the Telethon New Children's Hospital Research Fund (stage one) and Australia's National Health and Medicine Research Council (stage two). These funding bodies had no role in the study design, data collection, data analysis, data interpretation, or writing of this
257 258 259 260 261	Role of the funding source This trial is funded by the Telethon New Children's Hospital Research Fund (stage one) and Australia's National Health and Medicine Research Council (stage two). These funding bodies had no role in the study design, data collection, data analysis, data interpretation, or writing of this report. The conduct of this trial is overseen by an independent Data and Safety Monitoring

263

# 264 Results

- 265 Between March 7, 2018 and January 13, 2022, 153 infants were screened for eligibility (Figure 1),
- of whom 150 were randomised to wP versus aP for their 6-week pertussis vaccine dose (75 in
- 267 each group). Baseline and demographic characteristics were well balanced across mixed and aP-
- 268 only schedules as described in Table 1. Except for three infants in the mixed schedule arm, infants
- this cohort were born from an aP-vaccinated mother in the preceding pregnancy.

270

15

# 271 Table 1. Baseline and demographic characteristics.

	aP (n = 75)	wP (n = 75)	Overall (n = 150)	
History of atopic diseases in first degree relatives	- n (%)			
No	16 (21)	20 (27)	36 (24)	
Yes	58 (77)	54 (72)	112 (75)	
Unknown	1 (1)	1 (1)	2 (1)	
Sex - n (%)				
Female	36 (48)	38 (51)	74 (49)	
Male	39 (52)	37 (49)	76 (51)	
Household income - n (%)				
< \$18,000	1 (1)	0 (0)	1 (1)	
\$18,000 to \$37,000	0 (0)	1 (1)	1 (1)	
\$37,001 to \$87,000	5 (7)	2 (3)	7 (5)	
\$87,001 to \$180,000	34 (45)	42 (56)	76 (51)	
> \$180,000	35 (47)	30 (40)	65 (43)	
Maternal education - n (%)				
Secondary school	5 (7)	2 (3)	7 (5)	
TAFE or trade certificate (including diploma)	10 (13)	12 (16)	22 (15)	
Bachelor-level university degree	35 (47)	36 (48)	71 (47)	
Post-graduate university qualification	25 (33)	25 (33)	50 (33)	
Other parent's education - n (%)				
Secondary school	5 (7)	8 (11)	13 (9)	
TAFE or trade certificate (including diploma)	24 (32)	19 (25)	43 (29)	
Bachelor-level university degree	26 (35)	25 (33)	51 (34)	
Post-graduate university qualification	20 (27)	23 (31)	43 (29)	
Maternal country of birth - n (%)				
Australia	51 (68)	55 (73)	106 (71)	
United Kingdom	6 (8)	2 (3)	8 (5)	
Ireland	3 (4)	0 (0)	3 (2)	
Philippines	1 (1)	2 (3)	3 (2)	

## It is made available under a CC-BY-ND 4.0 International license .

16

Other	8 (11)	10 (13)	18 (12)
Missing	6 (8)	6 (8)	12 (8)
Other parent's country of birth - n (%)			
Australia	53 (71)	50 (67)	103 (69)
United Kingdom	3 (4)	7 (9)	10 (7)
New Zealand	1 (1)	4 (5)	5 (3)
Ireland	1 (1)	3 (4)	4 (3)
Other	11 (15)	4 (5)	15 (10)
Missing	6 (8)	7 (9)	13 (9)
Delivery type - n (%)			
Vaginal delivery	25 (33)	29 (39)	54 (36)
Elective caesarean section	21 (28)	17 (23)	38 (25)
Emergency caesarean section	12 (16)	18 (24)	30 (20)
Forceps/vacuum assisted delivery	17 (23)	11 (15)	28 (19)
ntrapartum antibiotics - n (%)			
No	48 (64)	47 (63)	95 (63)
Yes	27 (36)	27 (36)	54 (36)
Missing	0 (0)	1 (1)	1 (1)
leonatal antibiotics - n (%)			
No	66 (88)	71 (95)	137 (91)
Yes	9 (12)	4 (5)	13 (9)
Aaternal gravidity - n (%)			
1	43 (57)	31 (41)	74 (49)
2	18 (24)	19 (25)	37 (25)
3	9 (12)	14 (19)	23 (15)
4	3 (4)	6 (8)	9 (6)
5+	2 (3)	5 (7)	7 (5)

## Maternal parity - n (%)

1	53 (71)	46 (61)	99 (66)
2	14 (19)	22 (29)	36 (24)
3	7 (9)	4 (5)	11 (7)

## It is made available under a CC-BY-ND 4.0 International license .

4	1 (1)	3 (4)	4 (3)

#### Maternal dTpa in the preceding pregnancy - n (%)

5c-dTpa	21 (28)	20 (27)	41 (27)
3c-dTpa	43 (57)	39 (52)	82 (55)
Unknown	11 (15)	13 (17)	24 (16)
None	0 (0)	3 (4)	3 (2)

## Maternal dTpa last 5 years, excluding in the preceding pregnancy - n (%)

5c-dTpa	7 (9)	6 (8)	13 (9)
3c-dTpa	6 (8)	9 (12)	15 (10)
3c-dTpa-IPV	1 (1)	0 (0)	1 (1)
Unknown	22 (29)	25 (33)	47 (31)
None	39 (52)	35 (47)	74 (49)

### Maternal seasonal influenza vaccination during pregnancy - n (%)

No	14 (19)	10 (13)	24 (16)
Yes	61 (81)	65 (87)	126 (84)

### Mode of feeding - n (%)

Exclusively breastfed	50 (67)	52 (69)	102 (68)
Exclusively formula-fed	6 (8)	4 (5)	10 (7)
Both breastfed and formula-fed	18 (24)	19 (25)	37 (25)
Both breastfed and started on solids	1(1)	0 (0)	1(1)

#### Cat ownership - n (%)

No	59 (79)	63 (84)	122 (81)
Inside	5 (7)	3 (4)	8 (5)
Inside and outside	11 (15)	9 (12)	20 (13)

## Dog ownership - n (%)

No	35 (47)	39 (52)	74 (49)
Inside	14 (19)	10 (13)	24 (16)
Outside	4 (5)	3 (4)	7 (5)
Inside and outside	22 (29)	23 (31)	45 (30)

### Child attends day care - n (%)

## It is made available under a CC-BY-ND 4.0 International license .

18

No	75 (100)	75 (100)	150 (100)			
Number of siblings - n (%)						
0	51 (68)	41 (55)	92 (61)			
1	14 (19)	22 (29)	36 (24)			
2	9 (12)	5 (7)	14 (9)			
3+	1 (1)	4 (5)	5 (3)			
Missing	0 (0)	3 (4)	3 (2)			

## Apgar score, 1 minute - n (%)

< 8	9 (12)	9 (12)	18 (12)
8	5 (7)	5 (7)	10 (7)
9	59 (79)	61 (81)	120 (80)
10	1 (1)	0 (0)	1 (1)
Missing	1 (1)	0 (0)	1 (1)

## Apgar score, 5 minute - n (%)

< 8	0 (0)	3 (4)	3 (2)
8	2 (3)	3 (4)	5 (3)
9	67 (89)	64 (85)	131 (87)
10	5 (7)	5 (7)	10 (7)
Missing	1 (1)	0 (0)	1 (1)

#### Maternal ethnicity - n (%)<sup>1</sup>

European Caucasian	68 (45)	63 (42)	131 (44)	
Indian subcontinent	7 (5)	11 (7)	18 (6)	
Asian	5 (3)	9 (6)	14 (5)	
South American	1(1)	2 (1)	3 (1)	

#### Other parent's ethnicity - n (%)<sup>1</sup>

European Caucasian	71 (47)	72 (48)	143 (48)	
Indian subcontinent	6 (4)	4 (3)	10 (3)	
Asian	3 (2)	4 (3)	7 (2)	
South American	0 (0)	1 (1)	1 (0)	
Black African	0 (0)	1 (1)	1 (0)	
Indigenous Australia	1 (1)	0 (0)	1 (0)	

## It is made available under a CC-BY-ND 4.0 International license .

19

#### Infant's ethnicity - n (%)<sup>1</sup>

European Caucasian	72 (48)	73 (49)	145 (48)
Indian subcontinent	10 (7)	12 (8)	22 (7)
Asian	6 (4)	11 (7)	17 (6)
South American	1 (1)	2 (1)	3 (1)
Black African	0 (0)	1 (1)	1 (0)
Indigenous Australia	1 (1)	0 (0)	1 (0)

#### Birth measurements - Median (Q1–Q3)

Gestational age at delivery (weeks)	39 (38–39)	38 (38–39)	38 (38–39)	
Weight (g)	3345 (3023–3601)	3454 (3182–3765)	3410 (3110–3664)	
Weight missing - n (%)	1 (1)	0 (0)	1 (1)	
Length (cm)	50 (49–51)	51 (49–52)	50 (49–51) 1 (1)	
Length missing - n (%)	1 (1)	0 (0)		
Head circumference (cm)	35 (34–36)	35 (34–36)	35 (34–36)	
Head circumference missing - n (%)	1 (1)	0 (0)	1 (1)	

#### Baseline measurements - Median (Q1-Q3)

Age (days)	48 (45–50)	47 (44–50)	48 (45–50) 4888 (4361–5328)	
Weight (g)	4830 (4308–5315)	5025 (4515–5385)		
Weight missing - n (%)	0 (0)	0 (0)	0 (0)	
Length (cm)	56 (55–58)	56 (55–58)	56 (55–58) 0 (0)	
Length missing - n (%)	0 (0)	0 (0)		
Head circumference (cm)	38 (38–39)	38 (38–40)	38 (38–39)	
Head circumference missing - n (%)	1 (1)	2 (3)	3 (2)	

<sup>1</sup> Multiple ethnicities may apply, so percentages may not sum to 100.

5c-dTpa: 5-component diphtheria-tetanus-acellular pertussis combination vaccine (reduced antigen formulation; includes pertussis toxoid, filamentous haemagglutinin, pertactin, and fimbriae types 2 and 3); 3c-dTpa: 3-component diphtheria-tetanus-acellular pertussis combination vaccine (reduced antigen formulation; includes pertussis toxoid, filamentous haemagglutinin, and pertactin); IPV: inactivated poliovirus vaccine.

# 272 All available IgG responses are summarised in Figure 2 and in the supplementary document; per

273 protocol analyses are included in the <u>supplementary document</u>.

#### It is made available under a CC-BY-ND 4.0 International license .

20

At 6 months old, 72 of 75 infants (96%) in the aP-only schedule group and 68 of 75 infants (91%) in the mixed schedule group had immunogenicity outcome data available (Figure 1). At 7 months old, 69 of 75 infants (92%) in the aP-only schedule group and 67 of 75 infants (89%) in the mixed schedule group had immunogenicity outcome data available (Figure 1).

278 At 7 months old, 68 of 69 infants in the aP-only group (99%) and 66 of 67 infants in the mixed 279 schedule group (99%) had PT-, FHA-, PRN-, TT-, and DT-IgG concentrations above the specified 280 seropositivity/seroprotective thresholds (see supplementary document). In the mixed schedule 281 group, infants had PT-IgG GMC of 4.9 IU/mL at approximately 6 months old which increased to 282 26.4 IU/mL at approximately 7 months old. In the aP-only schedule group, infants had PT-IgG 283 GMC of 13.7 IU/mL at approximately 6 months old which increased to 27.7 IU/mL at 284 approximately 7 months old. The posterior median GMR for PT-IgG (mixed schedule/aP-only schedule) at 7 months old was 0.98 (95% Bayesian credible interval [Crl] 0.77 to 1.26; probability 285 286 (GMR > 2/3) > 0.99). A decrease in IgG GMCs for FIM 2/3 and an increase in IgG GMCs for FHA, PRN, DT, and TT were observed at 7 months compared to 6 months old for both study groups 287 288 (see supplementary document). The remaining IgG GMR posterior summaries are included in 289 Table 2.

- 290
- 291

21

# 292 Table 2. IgG GMR posterior summaries (mixed schedule group/aP-only group) and non-

## 293 inferiority probability, diphtheria, tetanus, and pertussis antigens

	Mean ± std	Median	95% Crl	Pr (> 1)	Pr (> 2/3)
Diphtheria toxoid					
6-month	$1.11 \pm 0.14$	1.10	(0.85, 1.42)	0.77	> 0.99
7-month	$1.36 \pm 0.16$	1.35	(1.07, 1.70)	0.99	> 0.99
7/6-month (GMFR)	$1.24 \pm 0.14$	1.23	(0.97, 1.55)	0.96	_
Filamentous haemagglutini	ı				
6-month	$0.36 \pm 0.05$	0.36	(0.28, 0.46)	0.00	0.00
7-month	$0.70 \pm 0.08$	0.69	(0.56, 0.87)	0.00	0.67
7/6-month (GMFR)	1.97 ± 0.24	1.96	(1.55, 2.47)	> 0.99	_
Fimbriae 2/3					
6-month	1.96 ± 0.59	1.88	(1.04, 3.34)	0.98	> 0.99
7-month	1.85 ± 0.53	1.78	(1.01, 3.09)	0.98	> 0.99
7/6-month (GMFR)	0.95 ± 0.07	0.95	(0.82, 1.09)	0.23	_
Pertactin					
6-month	$1.03 \pm 0.17$	1.01	(0.74, 1.40)	0.53	> 0.99
7-month	$0.80 \pm 0.12$	0.79	(0.59, 1.07)	0.06	0.88
7/6-month (GMFR)	$0.79 \pm 0.13$	0.78	(0.57, 1.06)	0.06	_
Pertussis toxin					
6-month	$0.37 \pm 0.04$	0.37	(0.30, 0.46)	0.00	0.00
7-month	$0.99 \pm 0.13$	0.98	(0.77, 1.26)	0.43	> 0.99
7/6-month (GMFR)	2.64 ± 0.27	2.63	(2.15, 3.21)	> 0.99	_
Tetanus toxoid					
6-month	$1.16 \pm 0.14$	1.15	(0.92, 1.45)	0.89	> 0.99
7-month	$1.16 \pm 0.12$	1.15	(0.93, 1.42)	0.91	> 0.99
7/6-month (GMFR)	$1.01 \pm 0.10$	1.00	(0.83, 1.21)	0.50	_

GMR, geometric mean ratio; std, standard deviation; Crl: credible interval; Pr, probability; GMFR, geometric mean fold rise

It is made available under a CC-BY-ND 4.0 International license .

- 295 Total IgE and IgE responses to hen's egg and TT antigens are summarised in Table 3, Figure 3, and
- 296 in the supplementary document.

297

#### It is made available under a CC-BY-ND 4.0 International license .

23

# 298 Table 3. Sample IgE concentration summaries ( $kU_{[a]}/L$ ) by allergen type and assigned

# 299 vaccination schedule.

								wP				
	n	GMC	Q1–Q3	Min-Max	≥0.01	≥0.1	n	GMC	Q1-Q3	Min–Max	≥0.01	≥0.1
Total IgE												
6-month	67	4.76	2.34–10.11	0.40–121.43	100%	100%	61	6.11	2.40-12.43	0.19– 141.38	100%	100%
7-month	66	6.36	2.69–11.72	0.52–241.99	100%	100%	57	7.71	2.66–16.30	0.52– 148.70	100%	100%
Tetanus toxoid IgE												
6-month	67	0.00	0.00–0.00	0.00-0.22	12%	1%	61	0.00	0.00-0.00	0.00-1.71	21%	7%
7-month	66	0.00	0.00–0.00	0.00-0.20	21%	3%	57	0.00	0.00-0.00	0.00-0.82	21%	7%
Egg white IgE												
6-month	67	0.00	0.00–0.02	0.00–14.91	36%	18%	61	0.00	0.00-0.02	0.00-3.00	26%	20%
7-month	67	0.00	0.00–0.04	0.00–39.50	54%	24%	57	0.00	0.00-0.03	0.00-4.51	42%	19%
Whole egg IgE												
6-month	67	0.00	0.00-0.02	0.00-14.85	40%	18%	60	0.00	0.00-0.04	0.00-3.51	42%	22%
7-month	67	0.00	0.00-0.04	0.00-33.70	52%	22%	57	0.00	0.00-0.04	0.00-5.16	40%	21%

300 GMC, geometric mean concentrations. Q1-Q3: first and third quartile. Min-Max, range: minimum and maximum. Values of 0.00 set to 0.005 for

301 calculation of sample GMC.

302	At approximately 7 months old, total IgE levels ≥ 0.1 kU/L were observed in all infants assigned
303	to the mixed schedule (GMC = 7.71 kU/L) and to the aP-only schedule (GMC = $6.36$ kU/L; Table
304	3). The posterior median GMR for total IgE (mixed schedule /aP-only schedule) was 1.14 (95% CrI
305	0.75 to 1.72; probability (GMR < 1) 0.27). The estimated posterior risk and risk difference
306	between the mixed schedule group and the aP-only group for TT, egg white, and whole egg IgE
307	are presented in Table 4 and in the supplementary document.

308

#### It is made available under a CC-BY-ND 4.0 International license .

25

# 309 Table 4. Posterior risk and risk difference for tetanus toxoid and hen's egg IgE quantitation by

## 310 age and pertussis schedule.

	Ma	rginal Pr (IgE ≥ 0.01), N		Odds ratios			
	aP	wP	wP-aP	Pr (wP-aP <0)	Conditional	Marginal	
Tetanus toxoid IgE							
Unadjusted							
6-month	0.15 (0.07,0.27)	0.21 (0.11, 0.34)	0.05 (-0.05,0.17)	0.17	2.69 (0.35,28.27)	1.40 (0.71, 3.39)	
7-month	0.22 (0.12, 0.35)	0.21 (0.11, 0.34)	-0.01 (-0.14, 0.13)	0.53	0.91 (0.07, 9.44)	0.97 (0.43, 2.14)	
Adjusted							
6-month	0.16 (0.08, 0.27)	0.21 (0.11, 0.33)	0.04 (-0.05, 0.15)	0.20	2.61 (0.27, 35.40)	1.33 (0.67, 3.11)	
7-month	0.22 (0.12, 0.34)	0.22 (0.12, 0.34)	0.00 (-0.12, 0.12)	0.52	0.95 (0.06, 13.91)	0.98 (0.43, 2.26)	
Egg white IgE							
Unadjusted							
6-month	0.36 (0.24, 0.49)	0.27 (0.16, 0.40)	-0.09 (-0.23, 0.05)	0.90	0.37 (0.06, 1.69)	0.66 (0.33, 1.23)	
7-month	0.51 (0.38, 0.65)	0.44 (0.30, 0.59)	-0.07 (-0.23, 0.09)	0.80	0.50 (0.09, 2.60)	0.76 (0.38, 1.44)	
			Adjusted				
6-month	0.35 (0.24, 0.48)	0.28 (0.17, 0.41)	-0.07 (-0.20, 0.05)	0.86	0.36 (0.04, 2.35)	0.72 (0.35, 1.31)	
7-month	0.49 (0.37, 0.62)	0.46 (0.33, 0.59)	-0.03 (-0.19, 0.11)	0.68	0.63 (0.07, 5.67)	0.86 (0.43, 1.67)	
Whole egg IgE							
Unadjusted							
6-month	0.41 (0.29, 0.55)	0.40 (0.27, 0.54)	-0.01 (-0.15, 0.13)	0.57	0.85 (0.14, 4.90)	0.95 (0.52, 1.71)	
7-month	0.51 (0.37, 0.64)	0.42 (0.28, 0.56)	-0.09 (-0.24, 0.07)	0.87	0.35 (0.05, 2.26)	0.71 (0.36, 1.32)	
Adjusted							
6-month	0.41 (0.30, 0.54)	0.41 (0.28, 0.53)	-0.01 (-0.13, 0.12)	0.55	0.88 (0.11, 6.97)	0.96 (0.55, 1.72)	
7-month	0.49 (0.37, 0.62)	0.41 (0.28, 0.53)	-0.06 (-0.21, 0.08)	0.81	0.36 (0.03, 3.55)	0.75 (0.38, 1.43)	

311 Pr, probability, CrI, credible interval; aP, acellular pertussis vaccine; wP, whole-cell pertussis vaccine. All adjusted models included sex, birth order,

312 breastfeeding status, delivery method, family history of atopic disease, and parental income as baseline covariates.

313

26

The distribution of daily grades for solicited local and systemic adverse reactions following each vaccine occasion are presented in Figures 4, 5, and 6 and in the <u>supplementary document</u>. After the 6-week doses, 74 of 75 (99%) diary cards were returned in the mixed schedule group and 72 of 75 (96%) in the aP-only schedule group. Paracetamol use after the 6-week vaccine doses on more than one occasion was recorded among 59 of 75 (79%) wP and 52 of 75 (69%) aP recipients. A first dose of wP was more frequently followed by mild-to-moderate solicited local and systemic adverse reactions than aP (see <u>supplementary document</u>).

Self-limited grade 3 (severe) erythema and swelling were reported at the pertussis vaccine (1 of r4; 1%) and 13vPCV (1 of r4; 1%) injection-sites after a 6-week wP dose; none were reported after the 6-week aP dose (Figure 5 and <u>supplementary document</u>). No reports of severe erythema, swelling, or induration at the pertussis vaccine or 13vPCV injection-sites were recorded in either study group after the 4-month or 6-month vaccine doses. Severe pain was recorded at the pertussis vaccine injection-site after a 6-week wP dose (6 of r4; 8%), but not after a 6-week aP dose (0 of r2).

Fever  $\geq$  38.0° C was reported in 0 of 73 infants vaccinated with wP and 1 of 70 (1%) infants vaccinated with aP at 6 weeks old, in 3 of 70 infants (4%) in the mixed schedule group and in 4 of 72 (6%) infants in the aP-only schedule group at 4 months old, and in 1 of 68 infants (1%) in each study group at 6 months old.

The proportion of infants who experienced one or more severe (grade 3) solicited systemic adverse reactions was higher among those who received wP (14/74; 19%) than aP (8/72; 11%) at 6 weeks old, but similar after the 4-month (mixed schedule 9 of 71; 13% versus aP-only schedule

27

12 of 73; 16%) and 6-month aP doses (mixed schedule 5 of 69; 7% versus aP-only schedule 5 of
68; 7%). Severe irritability was reported in 11 of 74 (15%) wP versus 7 of 72 (10%) aP recipients
at 6 weeks old, in 8 of 71 (11%) in the mixed schedule group and 8 of 73 (11%) in the aP-only
schedule group at 4 months old, and in 5 of 69 (7%) in the mixed schedule group versus 4 of 68
(6%) in the aP-only schedule group at 6 months old.
On Day 6 post-vaccination at 6 weeks' old, 71 of 73 (97%) parents of wP recipients and 69 of 72

341 (96%) parents of aP recipients either agreed or strongly agreed that they would be happy for

342 their child to receive the same vaccine combination.

There were 7 SAEs among 5 participants within the first 6 months of follow-up; on blinded assessment, none were assessed to be related to the study vaccines. No hypotonic hyporesponsive episodes or breakthrough pertussis infections occurred in either group.

346

# 347 Discussion

348 We report the results of a randomised comparison of the immunogenicity, reactogenicity, and 349 IgE-mediated immune responses to a mixed wP/aP primary vaccine schedule versus the standard 350 aP-only schedule. Mixed priming (wP/aP/aP) using the WHO prequalified 5-in-1 wP vaccine 351 (Pentabio, PT Biofarma, Indonesia) and 3c-aP vaccine (Infanrix Hexa, GlaxoSmithKline, Australia) 352 formulation was non-inferior to the homologous aP-only schedule (aP/aP/aP) with respect to 353 anti-PT antibody titres at 6 and 7 months old. While almost all (99%) serum responses to DT, TT, 354 FHA, and PRN in the two treatment groups met their specified seropositivity/seroprotective 355 thresholds at 7 months old, PT and FHA IgG concentrations immediately before the 6-month aP 356 dose were lower in the mixed schedule group compared to the aP-only group. Given the lower 357 content of PT and FHA in wP versus aP-based vaccines, this finding was not unexpected; by one 358 month after the 6-month aP dose, PT concentrations were similar, but concentrations of FHA 359 remained lower in the mixed schedule compared to the aP-only schedule group.

Previous studies have found concentrations of antibodies to aP vaccine antigens were either similar or lower in infants primed with wP than in those primed with aP.<sup>22</sup> In addition, it has been speculated that maternal vaccination might cause greater interference of the immunogenicity of wP than aP vaccines in early infancy.<sup>22</sup> In our trial, almost all mothers had received aP in pregnancy, so their infants are likely to have had high levels of maternally-derived antibodies targeting aP vaccine antigens at the time of receipt of the 6-week vaccine doses.

A dose of wP at approximately 6 weeks old was more reactogenic than a dose of aP, with a higher frequency of solicited local and systemic adverse reactions which were mostly mild-to-moderate in severity. While after the 6-week doses severe local adverse reactions were seldom reported

29

and only described at the wP and 13vPCV injection sites, fever  $\ge$  38.0°C was only described in the aP-vaccine study group. The proportion of parents of wP-vaccinated infants who reported acceptability of the vaccination was very high and similar to that of parents of aP-vaccinated infants. The young age of administration of first dose of the vaccines and the routine use of prophylactic paracetamol may have attenuated the intensity of solicited reactions and possibly enhanced parental acceptance of wP.<sup>23</sup> The reactogenicity data were presented quarterly to an independent data safety and monitoring committee which supported continued enrolment.

376 A previous RCT suggested that therapeutic paracetamol administered within 48 hours post DTwP 377 vaccination does not interfere with IgG immune responses elicited by the vaccine antigens in 378 children receiving a homologous 2, 4, 6, and 18-month schedule.<sup>24</sup> More recently, a clinical trial 379 reported that prophylaxis with oral paracetamol had no effect on immunogenicity of a 380 combination aP vaccine, co-administered with 7v-PCV and a recombinant multicomponent meningococcal B vaccine at 2, 3, and 4 months old.<sup>25</sup> By contrast, in infants receiving a 381 combination aP vaccine co-administered with the 10-valent pneumococcal non-typeable 382 383 Haemophilus influenzae protein D-conjugate vaccine (PhiD-CV) at 3, 4, and 5-months old, 384 prophylactic rectal paracetamol was associated with reduced IgG responses to aP antigens and pneumococcal vaccine polysaccharides.<sup>26</sup> While the clinical significance of these findings is 385 386 uncertain, a follow-up study suggested that paracetamol prophylaxis had no impact on the 387 induction of PhiD-CV serotype-specific immunological memory or pneumococcal nasopharyngeal carriage as measured at 4 years old.<sup>27</sup> 388

389 Owing to evidence of improved long term pertussis protection among wP vaccine recipients, the 390 WHO recommends that countries using wP should only changeover to less reactogenic aP-only schedules where it is financially and programmatically feasible to provide frequent aP boosters,

391

30

including in pregnancy.<sup>28</sup> For countries which have already transitioned to an aP-only schedules, 392 393 mixed schedules may provide better long-lived protection against pertussis but confirmation of this would require the follow-up of many thousands of infants over many years. 394 395 Examining the immune responses driven by wP vaccine formulations is complex. The exact 396 concentrations of pertussis antigens within wP varies across formulations. Previous clinical trials 397 reported differences in immune responses between wP and aP-based vaccines administered in 398 homologous priming schedules and across various specific formulations of the two vaccine types. 399 Antibody responses to aP-specific antigens are generally higher among aP-vaccinated infants 400 than wP-vaccinated infants.<sup>29–31</sup> However, greater vaccine effectiveness has been documented 401 among school-aged children and adolescents who had received wP versus aP as their first dose.<sup>4</sup> 402 Pertussis-specific T-cell memory responses may be important in long-term protection after wP 403 combination vaccine and will be evaluated in these infants. 404 Observational studies suggest that laboratory-confirmed pertussis may be less likely among wP-405 primed versus aP-primed children, and among those receiving mixed schedules in which the first dose was wP versus aP.<sup>3,32</sup> A case-control study found that pertussis disease was less common 406 407 among children receiving a mixed schedule of wP/3c-aP versus 3c-aP only. No evidence was 408 found of a difference in the risk of pertussis among those vaccinated with a mixed wP/5c-aP 409 schedule versus those vaccinated with a with a 5c-aP formulation, although long-term differences cannot be excluded.<sup>33</sup> Another case-control study found that compared to a 5c-aP-410 only primary series, vaccination with one or more primary doses of a low-efficacy wP vaccine 411 412 formulation was associated with a lower risk of pertussis disease more than a decade after

### It is made available under a CC-BY-ND 4.0 International license .

31

priming.<sup>32</sup> None of the cited case-control analyses provided further details regarding the nature
of the first pertussis vaccine dose in the mixed schedules examined.

415 WHO-pregualified 5-in-1 wP vaccine formulations have been successfully introduced across 77 416 lower-income countries supported by Gavi. While earlier concerns about safety led to the 417 discontinuation of wP in Australia and other high-income countries, a 2021 meta-analysis of 15 418 RCTs (38,072 infants) found that any risk difference for SAEs in infants primed with wP versus aP 419 is likely to be small, ranging from three fewer to two more events per 1,000 children.<sup>34</sup> Similar to 420 our trial, the meta-analysis defined SAEs as event that resulted in death, were life-threatening, 421 required hospitalisation or prolongation of existing hospitalisation, or resulted in persistent or 422 significant disability or incapacity.<sup>34</sup> Our data are therefore consistent with the excellent safety 423 record of wP previously highlighted by the WHO, and support the ongoing use of wP.

We have previously observed that Australian children with IgE-mediated food allergy were less 424 425 likely than contemporaneous controls to have received one or more doses of wP in infancy.<sup>5</sup> We hypothesised that compared to a standard aP-only schedule, a mixed vaccine schedule 426 427 comprising an initial dose of wP could help promote the normal transition from a Th<sub>2</sub>-skewed to a balanced  $Th_1/Th_{17}/Th_2$  immunophenotype in early infancy, and thereby protect against IgE-428 429 mediated food allergy. Having previously noted that wP-primed infants were less likely than aP-430 primed infants to develop boosted vaccine-associated IgE responses,<sup>9</sup> we sought to confirm this 431 observation by testing for total, TT, and egg-specific IgE at 6 and 7 months. While the production 432 of specific IgE against DTaP antigens is known to only occur in a subset of vaccinated infants, children, or adults, the low TT-IgE concentrations observed in our study are not easily explained. 433 434 The detection of total and specific IgE were conducted using an autoanalyser IgE-based assay and

32

therefore interference by anti-allergen specific IgG is unlikely.<sup>35</sup> However, except for analyses carried out in Australia,<sup>9</sup> Belgium,<sup>7</sup> and the US,<sup>36</sup> most paediatric TT-specific IgE response data reported in the literature have been measured using RAST or other serological methods.<sup>8,37</sup> Thus, apart from the first group of cited studies, it is not possible to directly compare our IgE results with prior cohorts.

This study represents the first prospective randomised comparison of a novel mixed wP/aP versus aP-only schedule. We used a prequalified 5-in-1 combination vaccine formulation already widely adopted and available in Gavi supported countries, and the immunogenicity of each schedule was assessed using a validated multiplex fluorescent bead-based immunoassay.

444 The limitations of this study include uncertain generalisability since the study population 445 comprised a high proportion of infants of privately insured urban parents. Secondly, while our previous case-control study suggests that the potential allergy protective benefits of wP might 446 be confined to IgE-mediated peanut or tree nuts allergy,<sup>5</sup> stage one did not examine IgE 447 448 responses to these antigens. In addition, we were not powered to compare schedules for 449 important clinical outcomes, including pertussis disease. The mixed schedule was well accepted by the cohort of parents who consented to participate after being informed of the known 450 451 reactogenicity profile of wP; it is unclear whether the high acceptance of wP observed is generalisable to all parents. 452

In conclusion, our findings give support to the acceptable immunogenicity and reactogenicity of
the mixed primary schedule. These findings are relevant to countries where both wP and aP
vaccines are used and support the further evaluation of the clinical effects of mixed schedules.
We failed to find confirming immunological evidence of an attenuating effect of the mixed versus

457	the aP-only schedule on TT or egg-related IgE antibodies; owing to the unclear relationship
458	between these biomarkers and the subsequent development of IgE-mediated food allergy, a
459	clinically important effect cannot be excluded. In stage two, the effect of the mixed versus
460	standard schedule on the development of IgE-mediated food allergy by 12 months will be
461	assessed in up to 2000 infants using an adaptive design with prespecified stopping rules for
462	success or futility.

463

## 464 *Contributors*

465 Conceptualisation: JAM, KPP, DEC, CSW, NC, PBM, PGH, PCR, and TS. Data curation: GPC and JT. Formal analysis: JT and SM. Funding acquisition: JAM, KPP, DEC, NW, MG, CSW, NC, PCR, and TS. 466 Investigation: GPC, MJE, MOS, and SM. Methodology: MJE, JT, JAM, KPP, DEC, CSW, SM, NC, PCR, 467 468 and TS. Project administration: MJE. Software: JT. Supervision: MJE, MOS, PCR, and TS. 469 Validation: JT, SM, and MJ. Access and verification of the underlying (unblinded) data reported 470 in the manuscript: JT and MJ. Visualisation: JT. Writing – original draft: GPC. Writing – review and 471 editing: GP, MJE, JT, JAM, KPP, DEC, NW, MG, CSW, MOS, MJ, PGH, PCR, and TS. All authors 472 provided their input and approved the final version of this manuscript.

# 473 Declaration of interests

Unrelated to the work presented in this paper, DEC declared part time employment in DBV
Technologies, as well as DBV Technologies stock and stock options. DEC has also served on the
scientific advisory board for AllerGenis.

Unrelated to the work presented in this paper, MO is the non-remunerated Director of ASCIA, a
not-for-profit company and the peak professional body for allergy/immunology specialists in
Australia and New Zealand.

Unrelated to the work presented in this paper, PCR has served on pertussis vaccine scientific advisory boards for GlaxoSmithKline and Sanofi on behalf of his institution. He participated in multicentre vaccine trials of pertussis vaccines sponsored by industry, also unrelated to the work presented in this paper. He has received no personal remuneration for these activities.

484 All other authors report no potential conflicts.

## 485 Data sharing

Data from the study will be available at the completion of follow-up, analysis and reporting of OPTIMUM stage two; no end date. Deidentified, individual participant data and a data dictionary defining each field in the set, will be made available to researchers who provide a methodologically sound proposal to the corresponding author (TS), subject to a signed data access agreement and any necessary ethics approvals (see ANZCTR trial registration). The study protocol and statistical analysis plan are published, other study related documentation is available on request.

## 493 Acknowledgement

494 This trial is funded by the Telethon New Children's Hospital Research Fund (stage one) and 495 Australia's National Health and Medicine Research Council (stage two). GPC was supported by a 496 Stan Perron Post-PhD Career Launching Award, the Australian Department of Education and Training Endeavour Scholarship, as well as top-up scholarships from the Wesfarmers Centre of 497 498 Vaccine and Infectious Diseases at the Telethon Kids Institute and the Forrest Research 499 Foundation. KPP is supported by an NHMRC Investigator Grant and a Melbourne Children's 500 Clinician-Scientist Fellowship. SM was supported by the Australian Government Research 501 Training Program Scholarship, the Stan Perron Excellence Award, and top-up scholarships from 502 the UWA Safety Net, Wesfarmers Centre of Vaccine and Infectious Diseases, and the Stan Perron 503 Foundation. TS is supported by an MRFF Investigator Award (MRF1195153). We thank the 504 parents and infants who took part in stage one of this trial for their commitment and continuous 505 support. We acknowledge Jane Jones and all members of the Vaccine Trials Group at the Telethon

506 Kids Institute, who were involved in the conduct of stage one of the OPTIMUM study. We would 507 also like to express our gratitude to Kylie Rogers (data manager) and the independent data safety 508 monitoring committee for their valuable contributions and detailed oversight. We thank 509 Catherine Hughes (AM), consumer representative in the OPTIMUM study Steering Committee 510 Group for her valuable input in the design and conduct of this study

- 511 **Figure 1: Trial profile.** *Legend: \*Refers to the same study participant.*
- 512 Figure 2. IgG concentration boxplots by antigen type, age, and assigned treatment, pertussis
- 513 and other antigens. Horizontal dotted line indicates antigen-specific seropositive threshold.
- 514 Legend: PT, pertussis toxin; PRN, pertactin, FIM2/3, fimbriae 2/3; FHA, filamentous hemagglutinin
- 515 *DT, diphtheria toxin; TT, tetanus toxoid.*
- 516 **Figure 3. IgE concentrations by allergen type, age, and assigned schedule.**
- 517 Figure 4. Maximum injection site reaction size in the 7 days after the 6-week vaccine doses
- 518 Figure 5. Injection site pain in the 7 days after the 6-week vaccine doses.
- 519 Figure 6. Highest intensity grade for systemic reactions after the 6-week vaccine doses.

## 520 References

- 521 1 Zhang L, Prietsch SOM, Axelsson I, Halperin SA. Acellular vaccines for preventing whooping 522 cough in children. *Cochrane Database Syst Rev* 2014; **2014**: CD001478.
- Diavatopoulos DA, Mills KHG, Kester KE, *et al.* PERISCOPE: Road towards effective control of
   pertussis. *Lancet Infect Dis* 2019; **19**: e179–86.
- 525 3 Sheridan SL, Ware RS, Grimwood K, Lambert SB. Number and order of whole cell pertussis 526 vaccines in infancy and disease protection. *JAMA* 2012; **308**: 454–6.
- Liko J, Robison SG, Cieslak PR. Priming with whole-cell versus acellular pertussis vaccine. *N Engl J Med* 2013; 368: 581–2.
- 529 5 Estcourt MJ, Campbell DE, Gold MS, *et al.* Whole-cell pertussis vaccination and decreased risk
  of IgE-mediated food allergy: a nested case-control study. *J Allergy Clin Immunol Pract* 2020;
  531 8: 2004–14.
- 6 da Silva Antunes R, Babor M, Carpenter C, *et al.* Th1/Th17 polarization persists following
  whole-cell pertussis vaccination despite repeated acellular boosters. *J Clin Invest* 2018; **128**:
  3853–65.
- 535 7 Mascart F, Hainaut M, Peltier A, Verscheure V, Levy J, Locht C. Modulation of the infant
   536 immune responses by the first pertussis vaccine administrations. *Vaccine* 2007; 25: 391–8.
- Aalberse RC, Grüber C, Ljungman M, *et al.* Further investigations of the IgE response to tetanus
   and diphtheria following covaccination with acellular rather than cellular Bordetella pertussis.
   *Pediatr Allergy Immunol* 2019; **30**: 841–7.
- Holt PG, Snelling T, White OJ, *et al.* Transiently increased IgE responses in infants and preschoolers receiving only acellular diphtheria-pertussis-tetanus (DTaP) vaccines compared to
  those initially receiving at least one dose of cellular vaccine (DTwP) Immunological curiosity
  or canary in the mine? *Vaccine* 2016; **34**: 4257–62.
- 544 10 Ausiello CM, Urbani F, la Sala A, Lande R, Cassone A. Vaccine- and antigen-dependent type 1
   545 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular
   546 pertussis vaccines. Infect Immun 1997; 65: 2168–74
- 547 11 Nilsson L, Grüber C, Granström M, Björkstén B, Kjellman NI. Pertussis IgE and atopic disease.
   548 Allergy 1998; 53: 1195–201.
- 12 Pérez Chacón G, Estcourt MJ, Totterdell J, *et al.* OPTIMUM study protocol: an adaptive
   randomised controlled trial of a mixed whole-cell/acellular pertussis vaccine schedule. *BMJ Open* 2020; **10**: e042838.

13Totterdell JA, Pérez Chacón G, Estcourt MJ, *et al.* Statistical analysis plan for the OPTIMUM
 Study: Optimising Immunisation Using Mixed Schedules, an adaptive randomised controlled
 trial of a mixed whole-cell/acellular pertussis vaccine schedule. *Trials* 2022; 23.

- 55514Australian Government Department of Health and Aged Care. The Australian Immunisation556Handbook.[Internet].Available657Handbook.
- 557 https://www.health.gov.au/resources/publications/the-australian-immunisation-handbook.
- 558 Accessed: Oct 14, 2023.
- 15 National Health and Medical Research Council. The Australian Immunisation Handbook. 6thed. Canberra; 1997.
- 16 National Health and Medical Research Council. NHMRC guidance: Safety monitoring and
   reporting. [Internet]. Available from: https://www.nhmrc.gov.au/sites/default/files/2023 03/NHMRC-guidance-safety-monitoring-and-reporting.pdf. Accessed: Dec 17, 2023.
- 17 McAlister SM, van den Biggelaar AHJ, Thornton RB, Richmond PC. Optimising a 6-plex tetanus diphtheria-pertussis fluorescent bead-based immunoassay. *MethodsX* 2021; 8: 101360.
- 18Plotkin SA. Correlates of protection induced by vaccination. *Clin Vaccine Immunol* 2010; 17:
  1055–65.
- 19 World Health Organization. Immunological basis for immunization: module 2: diphtheria update 2009. Geneva: World Health Organization, 2009. Available from:
  https://iris.who.int/handle/10665/44094. Accessed Dec 16, 2023.
- 571 20 World Health Organization. The immunological basis for immunization series: module 3:
  572 tetanus. Geneva: World Health Organization, 2018. Available from:
  573 https://iris.who.int/handle/10665/275340. Accessed Dec 16, 2023.
- 574 21WHO Expert Committee on Biological Standardization. Guidelines on clinical evaluation of
   575 vaccines: regulatory expectations. Geneva: World Health Organization, 2017. Available from:
   576 https://cdn.who.int/media/docs/default-source/prequal/vaccines/who-trs-1004-web-annex 577 9.pdf. Accessed Dec 16, 2023.
- 578 22 Edwards KM, Berbers GAM. Immune responses to pertussis vaccines and disease. *J Infect Dis* 579 2014; **209**: S10–5.
- 23 Miller E, Ashworth LA, Redhead K, Thornton C, Waight PA, Coleman T. Effect of schedule on
   reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value
   of laboratory tests as predictors of clinical performance. *Vaccine* 1997; 15: 51–60.
- 24Long SS, Deforest A, Smith DG, Lazaro C, Wassilak SGF, Pennridge Pediatric Associates.
   Longitudinal study of adverse reactions following diphtheria-tetanus-pertussis vaccine in infancy. *Pediatrics* 1990; 85: 294–302.

- 25 Prymula R, Esposito S, Zuccotti GV, *et al.* A phase 2 randomized controlled trial of a
  multicomponent meningococcal serogroup B vaccine (I). *Hum Vaccin Immunother* 2014; **10**:
  1993–2004.
- 26 Prymula R, Siegrist C-A, Chlibek R, *et al.* Effect of prophylactic paracetamol administration at
   time of vaccination on febrile reactions and antibody responses in children: two open-label,
   randomised controlled trials. *Lancet* 2009; **374**: 1339–50.
- 27 Prymula R, Habib A, François N, Borys D, Schuerman L. Immunological memory and
   nasopharyngeal carriage in 4-year-old children previously primed and boosted with 10-valent
   pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV)
   with or without concomitant prophylactic paracetamol. *Vaccine* 2013; **31**: 2080–8.
- 596 28 Pertussis Vaccines: WHO Position Paper, August 2015—Recommendations. *Vaccine* 2016; 34:
  597 1423–5.
- 29 Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J
   Med 1996; 334: 349–55.
- 30Greco D, Salmaso S, Mastrantonio P, *et al.* A controlled trial of two acellular vaccines and one
  whole-cell vaccine against pertussis. Progetto Pertosse Working Group. *N Engl J Med* 1996;
  334: 341–8.
- 31 Olin P, Rasmussen F, Gustafsson L, Hallander HO, Heijbel H. Randomised controlled trial of
   two-component, three-component, and five-component acellular pertussis vaccines
   compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines.
   *Lancet* 1997; **350**: 1569–77.
- 608 32 Schwartz KL, Kwong JC, Deeks SL, *et al.* Effectiveness of pertussis vaccination and duration of 609 immunity. *Can Med Assoc J* 2016; **188**: E399–406.
- 33 Carvalho CFA, Andrews N, Dabrera G, *et al.* National outbreak of pertussis in England, 20112012: a case-control study comparing 3-component and 5-component acellular vaccines with
  whole-cell pertussis vaccines. *Clin Infect Dis* 2020; **70**: 200–7.
- 34Pérez Chacón G, Ramsay J, Brennan-Jones CG, *et al.* Whole-Cell pertussis vaccine in early
  infancy for the prevention of allergy in children. *Cochrane Database Syst Rev* 2021; 9:
  CD013682.
- 35 van Hage M, Hamsten C, Valenta R. ImmunoCAP assays: Pros and cons in allergology. J Allergy
   *Clin Immunol* 2017; 140: 974–7.
- 36Ownby DR, Partridge ME, Wegienka GR, *et al.* Influence of dose and frequency of antigen
  injection on IgE development in young children: a comparison of fire ant stings and tetanus
  immunizations. *Ann Allergy Asthma Immunol* 2009; **103**: 337–41.

- 621 37 Grüber C, Lau S, Dannemann A, Sommerfeld C, Wahn U, Aalberse RC. Down-regulation of IgE
- and IgG4 antibodies to tetanus toxoid and diphtheria toxoid by covaccination with cellular
- 623 Bordetella pertussis vaccine. *J Immunol* 2001; **167**: 2411–7.



Figure 1: Trial profile. \*Refers to the same study participant.



Figure 2. IgG concentration boxplots by antigen type, age, and assigned treatment, pertussis and other antigens. Horizontal dotted line indicates antigen-specific seropositive threshold. PT, pertussis toxin; PRN, pertactin, FIM2/3, fimbriae 2/3; FHA, filamentous hemagglutinin DT, diphtheria toxin; TT, tetanus toxoid.



Figure 3. IgE concentrations by allergen type, age, and assigned schedule.



Figure 4. Maximum injection site reaction size in the 7 days after the 6-week vaccine doses.



Figure 5. Injection site pain in the 7 days after the 6-week vaccine doses.



Grade 1: easily tolerated

Grade 2: interferes with normal everyday activities

Grade 3: prevents normal everyday activities or requires significant medical intervention

Figure 6. Highest intensity grade for systemic reactions after the 6-week vaccine doses.